← Back to Search

Immunomodulator

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Phase 2

Waitlist Available

Led By Christopher Gibbons, MD

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

Awards & highlights

All Individual Drugs Already Approved

Summary

This trial tests a treatment with healthy antibodies on patients with nerve damage and harmful antibodies. The goal is to see if this treatment can improve nerve health and reduce pain. This treatment has been used for nearly three decades for various neurological diseases.

Eligible Conditions

Peripheral Neuropathy
Small Fiber Neuropathy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays). for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The Change in Nerve Fiber Density Between Visits 1 and 8.

Secondary study objectives

2) The Difference in Change Between Quantified Utah Early Neuropathy Examination Scores, Between Treatment and Placebo Groups Between Visits 1 and 8.

The Change in Neuropathic Pain Severity Between Visits 1 and 8.

Side effects data

From 2022 Phase 2 trial • 20 Patients • NCT03401073

90%

Infusion reaction

100%

80%

60%

40%

20%

Study treatment Arm

0.9% Sodium Chloride

Intravenous Immunoglobulin

Awards & Highlights

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Intravenous ImmunoglobulinExperimental Treatment1 Intervention

The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments

Group II: 0.9% Sodium ChloridePlacebo Group1 Intervention

The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Human immunoglobulin G

FDA approved

Do I qualify?Apply below to find out